Baker Bros

Baker Brothers Advisors, a hedge fund run by Julian and Felix Baker, disclosed after Monday's market close it acquired 106,800 shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) for $7.28 per share. BioCryst Pharmaceuticals is a biotechnology company that develops small molecule drugs...